External validation of a nomogram predicting mortality in patients with adrenocortical carcinoma.

TY - JOUR

T1 - External validation of a nomogram predicting mortality in patients with adrenocortical carcinoma.

AU - Zini, Laurent

AU - Capitanio, Umberto

AU - Jeldres, Claudio

AU - Lughezzani, Giovanni

AU - Sun, Maxine

AU - Shariat, Shahrokh F

AU - Isbarn, Hendrik

AU - Arjane, Philippe

AU - Widmer, Hugues

AU - Perrotte, Paul

AU - Graefen, Markus

AU - Montorsi, Francesco

AU - Karakiewicz, Pierre I

PY - 2009

Y1 - 2009

N2 - OBJECTIVE To develop nomograms predicting cancer-specific and all-cause mortality in patients managed with either surgery or no surgery for adrenocortical carcinoma (ACC). PATIENTS AND METHODS The models were developed in 205 patients with ACC and externally validated using 207 other patients with ACC, identified in the 1973-2004 Surveillance, Epidemiology and End Results database. The predictors comprised age, gender, race, stage and surgery status. Nomograms based on Cox regression model-derived coefficients were used for predicting the cancer-specific and all-cause mortality, and were tested using area under the receiver operating characteristics (ROC) curve. RESULTS In cancer-specific analyses, the median survival of patients within the development cohort was 26 months, vs 71 months in the external validation cohort (P <0.001). In overall survival analyses, the median values were 21 vs 32 months for, respectively, the development and the external validation cohort (P <0.001). Three variables (age, stage and surgical status) were included in the nomograms predicting cancer-specific and all-cause mortality. In the external validation cohort, the nomograms achieved between 72 and 80% accuracy for prediction of cancer-specific or all-cause mortality at 1-5 years after either surgery or diagnosis of ACC for non-surgical patients. CONCLUSION Our models are the first standardized and individualized prognostic tools for patients with ACC. Their accuracy was confirmed within a large external population-based cohort of patients with ACC.

AB - OBJECTIVE To develop nomograms predicting cancer-specific and all-cause mortality in patients managed with either surgery or no surgery for adrenocortical carcinoma (ACC). PATIENTS AND METHODS The models were developed in 205 patients with ACC and externally validated using 207 other patients with ACC, identified in the 1973-2004 Surveillance, Epidemiology and End Results database. The predictors comprised age, gender, race, stage and surgery status. Nomograms based on Cox regression model-derived coefficients were used for predicting the cancer-specific and all-cause mortality, and were tested using area under the receiver operating characteristics (ROC) curve. RESULTS In cancer-specific analyses, the median survival of patients within the development cohort was 26 months, vs 71 months in the external validation cohort (P <0.001). In overall survival analyses, the median values were 21 vs 32 months for, respectively, the development and the external validation cohort (P <0.001). Three variables (age, stage and surgical status) were included in the nomograms predicting cancer-specific and all-cause mortality. In the external validation cohort, the nomograms achieved between 72 and 80% accuracy for prediction of cancer-specific or all-cause mortality at 1-5 years after either surgery or diagnosis of ACC for non-surgical patients. CONCLUSION Our models are the first standardized and individualized prognostic tools for patients with ACC. Their accuracy was confirmed within a large external population-based cohort of patients with ACC.

M3 - SCORING: Zeitschriftenaufsatz

JO - BJU INT

JF - BJU INT

SN - 1464-4096

ER -